close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Arcutis Biotherapeutics, Inc. - Common stock (NQ:ARQT)

24.81 -0.27 (-1.08%)
Streaming Delayed Price Updated: 1:43 PM EDT, Aug 24, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Arcutis Biotherapeutics, Inc. - Common stock

< Previous 1 2 3 4 5 6 7 Next >
Arcutis Biotherapeutics (NASDAQ:ARQT): A Decent Value Stock With Growth Momentum ↗
Via Chartmill
Arcutis Biotherapeutics (NASDAQ:ARQT) Pairs High Growth Momentum with a Breakout Setup ↗
Via Chartmill
Arcutis Biotherapeutics (NASDAQ:ARQT) Matches Navellier's Growth Playbook With Accelerating Fundamentals ↗
Via Chartmill
News headline image
Arcutis (ARQT) Q2 2026 Earnings Call Transcript ↗
ZORYVE franchise revenue surged 59% year-over-year, driving profitability. 
Via The Motley Fool
Topics Earnings Intellectual Property
Arcutis Biotherapeutics (NASDAQ:ARQT) Pairs Strong Growth with a Timely Technical Setup ↗
Via Chartmill
News headline image
Arcutis President and CEO Todd Watanabe Sells 4,375 Shares for $114,275 as Q2 Results Demonstrate Profitability ↗
Watanabe's sale was non-discretionary, executed to cover tax withholding on vesting RSUs. Watanabe retains 950,000+ shares valued at $24.65 million, signaling continued confidence. 
Via The Motley Fool
Topics Regulatory Compliance
Arcutis Biotherapeutics (NASDAQ:ARQT) Jumps on Q2 Beat and Raised Guidance ↗
Via Chartmill
Arcutis Biotherapeutics (NASDAQ:ARQT) Shows High Growth Momentum and Breakout Setup ↗
Via Chartmill
News headline image
Arcutis Biotherapeutics Q2 Earnings Call Highlights ↗
Arcutis Biotherapeutics (NASDAQ:ARQT) reported second-quarter 2026 net product revenue of $129.9 million, up 59% from the prior-year period and 23% sequentially, as demand for its ZORYVE topical... 
Via MarketBeat
Topics Earnings
Arcutis Biotherapeutics (NASDAQ:ARQT): An Affordable Growth Stock With Strong Revenue and Earnings Momentum ↗
Via Chartmill
Arcutis Biotherapeutics (NASDAQ:ARQT): High Growth Stock With a Strong Technical Setup ↗
Via Chartmill
News headline image
Arcutis vs. Vertex: Which Pharmaceutical Maker Stock Is a Better Buy in 2026? ↗
Arcutis doubled revenue last year while Vertex delivered strong profits and cash flow. Explore how each company stacks up on growth, risk, and value. 
Via The Motley Fool
Arcutis Director Sells $121,000 in Stock as ZORYVE Revenue Jumps 65% ↗
Via The Motley Fool
Arcutis Biotherapeutics Inc (NASDAQ:ARQT): A GARP Growth Play at a Reasonable Price ↗
Via Chartmill
Arcutis Biotherapeutics (NASDAQ:ARQT) Beats Q1 Revenue Estimates but Posts Wider-Than-Expected Loss; Shares Slide ↗
Via Chartmill
Arcutis Biotherapeutics Inc (NASDAQ:ARQT) Surpasses Q4 Estimates and Raises 2026 Sales Outlook ↗
Via Chartmill
Arcutis Biotherapeutics Inc (NASDAQ:ARQT) Shows Technical Breakout Setup ↗
Via Chartmill
News headline image
Arcutis Biotherapeutics Touts ZORYVE Growth, FDA Catalysts and Cash-Flow Positive Status ↗
Arcutis Biotherapeutics (NASDAQ:ARQT) executives said ZORYVE continues to post strong growth and outlined several regulatory and clinical catalysts expected over the next year, while emphasizing that... 
Via MarketBeat
News headline image
Trevi Therapeutics Is Up 100%, Pivotal bioVenture Adds Anyway. Here's Why That Matters. ↗
This clinical-stage biotech targets chronic pruritus and cough with its lead therapy for neurologically mediated diseases. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Arcutis (ARQT) Q1 2026 Earnings Transcript ↗
Arcutis (ARQT) Q1 2026 Earnings Transcript 
Via The Motley Fool
Arcutis Biotherapeutics Inc (NASDAQ:ARQT) Shows High-Growth Momentum and Strong Technical Setup ↗
Via Chartmill
News headline image
Arcutis Biotherapeutics Inc (NASDAQ:ARQT) Emerges as a High-Growth Momentum Breakout Candidate ↗
Arcutis Biotherapeutics (ARQT) combines strong earnings growth with a bullish technical setup, presenting a potential breakout opportunity for momentum investors. 
Via Chartmill
News headline image
Arcutis Stock Up 65% as Director Sells 10,000 Shares Under 10b5-1 Plan. Here's What Investors Should Know ↗
Focused on innovative dermatology treatments, this biopharma firm reported a notable insider sale amid a strong year for its shares. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Arcutis (ARQT) Q4 2025 Earnings Call Transcript ↗
Arcutis (ARQT) Q4 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
This Biopharma Stock Has Surged Nearly 100% and One Fund Just Locked in Gains With a $10 Million Exit ↗
Arcutis Biotherapeutics develops topical therapies for chronic skin conditions, with a portfolio targeting psoriasis and atopic dermatitis. 
Via The Motley Fool
News headline image
Arcutis Biotherapeutics (NASDAQ:ARQT) Combines High-Growth Momentum with Bullish Technical Setup ↗
Arcutis Biotherapeutics (ARQT) combines strong revenue growth & earnings momentum with a bullish technical chart setup, signaling a potential breakout opportunity. 
Via Chartmill
News headline image
Arcutis Stock Is Up 100% in a Year but Here’s Why One Fund Still Sold 1 Million Shares ↗
Even after cutting back, this remains the fund’s largest bet and the timing lines up with a pivotal stretch for Arcutis’ pipeline. 
Via The Motley Fool
News headline image
Fund Discloses Increased Mineralys Bet Amid 200% Stock Run as New Drug Application Nears ↗
When a clinical-stage biotech is sitting on nearly $600 million in cash and lining up an FDA filing, sharp investors stop arguing about the past rally and start debating what comes next. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
The Biotech Renaissance: Innovation and M&A Frenzy Spark a Historic Year-End Rally
As the curtains draw on 2025, the biotechnology sector has emerged as the undisputed champion of the equity markets, staging a dramatic year-end rally that has caught even the most optimistic analysts... 
Via MarketMinute
Topics ETFs Economy Intellectual Property
News headline image
This Biotech Stock Could Cure Your Portfolio's Pain ↗
A combination of a relatively low-risk approval process, growing sales, and a very attractive valuation based on management's peak sales estimations makes this biotech stock attractive. 
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at /week.